Related Experiment Video

Updated: Dec 28, 2025

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.9K

Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae

Matthew G K Benesch1,2, Xiaoyun Tang2, David N Brindley2

  • 1Discipline of Surgery, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL AlB 3V6, Canada.

Cancers
|February 12, 2020
PubMed

Insights

Autotaxin inhibitors, like GLPG1690, show promise for treating idiopathic pulmonary fibrosis and breast cancer. Blocking lysophosphatidic acid (LPA) signaling may overcome treatment resistance and reduce side effects.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The autotaxin-lysophosphatidate (LPA) axis is implicated in breast cancer progression and treatment resistance.
  • Tumor microenvironment and chronic inflammation are critical in cancer biology, with LPA as a key mediator.

Purpose of the Study:

  • To review current breast cancer therapy challenges.
  • To explore how blocking LPA signaling can offer novel adjuvant therapeutic options.
  • To discuss the potential of autotaxin inhibitors in improving therapeutic indexes for breast and other cancers.

Main Methods:

  • Review of preclinical and clinical data on autotaxin inhibitors.
  • Analysis of the role of the autotaxin-LPA axis in cancer.
  • Examination of therapeutic resistance mechanisms in breast cancer.

Main Results:

  • GLPG1690, an autotaxin inhibitor, is in Phase III trials for idiopathic pulmonary fibrosis.
  • Emerging evidence highlights LPA's role in breast cancer progression and resistance.
  • Autotaxin inhibitors may overcome resistance and reduce side effects like radiation-induced fibrosis.

Conclusions:

  • Blocking LPA signaling presents a potential strategy for novel adjuvant therapies in breast cancer.
  • Autotaxin inhibitors could improve the efficacy and safety of existing cancer treatments.
  • The clinical advent of autotaxin inhibitors may expand their application in various cancer types.
Keywords:
GLPG1690chemoresistancelipid phosphate phosphataseslysophosphatidic acidmetastasisradiotherapytumor microenvironment

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.1K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
880
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K